Magenta Therapeutics Inc. (MGTA)
$0.70
$-11.43
(-94.23%)
As on 11-Sep-2023 16:00EDT
Market cap
$45 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-65 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.2
-
Face value
--
-
Shares outstanding
60,664,700
7 Years Aggregate
CFO
$-318.43 Mln
EBITDA
$-412.96 Mln
Net Profit
$-377.94 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Magenta Therapeutics (MGTA)
| 74.9 | -11.4 | -0.1 | -63.8 | -53.9 | -44.0 | -- |
|
BSE Sensex*
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|
|
Magenta Therapeutics (MGTA)
| -91.0 | -43.5 | -48.3 | 166.0 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Magenta Therapeutics (MGTA)
|
0.7 | 45.1 | 0.0 | -69.8 | -- | -97.3 | -- | 0.5 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Magenta Therapeutics (MGTA)
Magenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune... diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Read more
-
Co-Founder, CEO, Pres & Director
Dr. Jason Gardner DPHIL, Ph.D.
-
Co-Founder, CEO, Pres & Director
Dr. Jason Gardner DPHIL, Ph.D.
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Magenta Therapeutics (MGTA)
What is the current share price of Magenta Therapeutics Inc (MGTA) Today?
The share price of Magenta Therapeutics Inc (MGTA) is $0.70 (NASDAQ) as of 11-Sep-2023 16:00 EDT. Magenta Therapeutics Inc (MGTA) has given a return of -53.92% in the last 3 years.
What is the current PB & PE ratio of Magenta Therapeutics Inc (MGTA)?
Since, TTM earnings of Magenta Therapeutics Inc (MGTA) is negative, P/E ratio is not available.
The P/B ratio of Magenta Therapeutics Inc (MGTA) is 0.54 times as on 20-Sep-2023, a 90 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-0.33 |
0.22 |
2021 |
-3.97 |
1.51 |
2020 |
-5.48 |
2.63 |
2019 |
-8.62 |
4.19 |
2018 |
-3.29 |
1.30 |
What is the 52 Week High and Low of Magenta Therapeutics Inc (MGTA)?
The 52-week high and low of Magenta Therapeutics Inc (MGTA) are Rs -- and Rs -- as of 07-Sep-2026.
What is the market cap of Magenta Therapeutics Inc (MGTA)?
Magenta Therapeutics Inc (MGTA) has a market capitalisation of $ 45 Mln as on 20-Sep-2023. As per SEBI classification, it is a company.
Should I invest in Magenta Therapeutics Inc (MGTA)?
Before investing in Magenta Therapeutics Inc (MGTA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.